Please join us for our next seminar Wednesday, August 23, at noon in the HudsonAlpha Auditorium featuring Michael Lotze, MD, who will present “Dying Dangerously: HMGB1, Histones, and K+ as Damage Associated Molecular Pattern Molecules (DAMPs) in the Tumor Microenvironment.”
Lotze’s research work includes modern cancer immunotherapy and gene therapy, T-cell, dendritic cell and cytokine therapies, and investigation of the role of mitochondria, metabolism, and unscheduled cell death in cancer. He has worked in the field of immunology and clinical medicine for over 30 years in translational research, particularly within cancer. For the first 20 years of his career at the NCI and then the UPCI, he developed the modern immunotherapies including Interleukin-2 therapy, IL-4 and IL-12 therapy, gene therapies and dendritic cell therapies for patients with melanoma.
Lotze is the co-inventor of 10 patents in dendritic cell vaccines, T-cell response to tumor antigens, and antigen discovery and serves as associate editor of the Journal of Immunotherapy. He is Chief Scientific Officer at Lion Biotechnologies; Professor of Surgery, Immunology, and Bioengineering at the University of Pittsburgh School of Medicine; Vice Chair of Research, Department of Surgery; Associate Director for Strategic Partnerships, University of Pittsburgh Cancer Institute; and Assistant Vice Chancellor for Sponsored Training Grants. He received his MD and BMSc from Northwestern University in Evanston, Ill. His academic career included surgical training at the University of Rochester as well as fellowships at MD Anderson Institute and the National Cancer Institute.
Jian Han, MD, PhD, HudsonAlpha faculty investigator and founder of iRepertoire and iCubate, will host the Wednesday seminar. More information on HudsonAlpha Research Seminars can be found at hudsonalpha.org/seminars.